|
ARF4 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.28689955861228E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.82710024466371E-10 |
| Normal-vs-Stage2 |
5.04279999979929E-08 |
| Normal-vs-Stage3 |
3.97760047121665E-10 |
| Normal-vs-Stage4 |
9.28368493191556E-13 |
| Stage1-vs-Stage2 |
9.502600E-01 |
| Stage1-vs-Stage3 |
3.316000E-01 |
| Stage1-vs-Stage4 |
1.397090E-03 |
| Stage2-vs-Stage3 |
5.050800E-01 |
| Stage2-vs-Stage4 |
2.112300E-02 |
| Stage3-vs-Stage4 |
5.392400E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62760027677677E-10 |
| Normal-vs-AfricanAmerican |
3.50340000000449E-05 |
| Normal-vs-Asian |
2.68519984025772E-10 |
| Caucasian-vs-AfricanAmerican |
8.959600E-01 |
| Caucasian-vs-Asian |
4.980800E-01 |
| AfricanAmerican-vs-Asian |
6.354200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.11739950625633E-10 |
| Normal-vs-Female |
4.990899915569E-10 |
| Male-vs-Female |
2.863200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.03359998337993E-09 |
| Normal-vs-Age(41-60Yrs) |
1.53160040206046E-10 |
| Normal-vs-Age(61-80Yrs) |
7.38364924757207E-12 |
| Normal-vs-Age(81-100Yrs) |
1.122430E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.007200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.096600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.870200E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.364600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.845900E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.906000E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.090400E-01 |
| Classical-VS-Follicular |
3.568600E-01 |
| Classical-VS-Other |
3.460400E-01 |
| Classical-VS-Normal |
5.86390047629948E-10 |
| Tall-VS-Follicular |
1.863780E-01 |
| Tall-VS-Other |
6.379400E-01 |
| Tall-VS-Normal |
6.13200001886582E-09 |
| Follicular-VS-Other |
3.283200E-01 |
| Follicular-VS-Normal |
2.9314000005165E-08 |
| Other-VS-Normal |
1.344980E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.10390038724029E-10 |
| Normal-vs-N1 |
5.80000492078625E-11 |
| N0-vs-N1 |
1.930970E-01 |
|
|
